) vaccines division, Sanofi Pasteur, recently announced the
approval of the expansion of the indication for Menactra
(meningococcal [Groups A, C, Y and W-135] polysaccharide
diphtheria toxoid conjugate vaccine) in Canada. Menactra is now
approved in Canada for patients, age between 9 months - 55
Menactra vaccines are used in patients (age of 9 months - 55
years) to prevent meningococcal meningitis and meningococcal
disease caused by strains A, C, Y and W-135 of the bacteria
We note that in November this year, data from a pivotal trial
of Menactra was published by the
Pediatric Infectious Disease Journal
(PIDJ). In the trial, Menactra, as a two-dose vaccine,
demonstrated a promising efficacy profile in infants and toddlers
aged between 9 months and 23 months. It was observed that the use
of Menactra provided protection against four clinically
Menactra was first approved in 2005 as meningococcal conjugate
vaccine for people aged between 11 years and 55 years.
Subsequently, the product's label was expanded to include infants
above 9 months. We note that meningococcal disease mostly occurs
in children aged less than five years and those in their
In the third quarter of 2012, Menactra generated sales of €208
million, accounting for approximately 14% of total vaccines sales
at Sanofi. In the US, Menactra sales inched up 0.6% to €195
Currently, approved vaccines for meningococcal diseases
) MenHibrix (meningococcal groups C and Y and haemophilus b
tetanus toxoid conjugate vaccine).
We expect Sanofi to continue to contain operating costs in
order to increase earnings in the face of weakening sales of some
of its biggest products. We also expect the company to pursue
Currently, we have a Neutral stance on Sanofi in the long run.
The company carries a Zacks #2 Rank (Buy) in the short run.
GLAXOSMITHKLINE (GSK): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.